Siemens Healthineers AG : The calm spell can be taken advantage of to put on new positions
Entry price | Target | Stop-loss | Potential |
---|
€53.74 |
€57 |
€52 |
+6.07% |
---|
Siemens Healthineers AG shares are locked into a trading range. This phase will eventually have to end with a return of a clear trend.
Summary● The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
● Over the past twelve months, analysts' opinions have been strongly revised upwards.
● Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
● Historically, the company has been releasing figures that are above expectations.
Weaknesses● The group shows a rather high level of debt in proportion to its EBITDA.
● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.76 times its estimated earnings per share for the ongoing year.
● The company's enterprise value to sales, at 3.15 times its current sales, is high.
● The company appears highly valued given the size of its balance sheet.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.